Purpose: Up to now, there has been limited investigation into cell therapy in the chronic phase of severe myocardial infarction (MI), and many questions remain concerning the contribution of the engrafted cells and especially their impact on the reperfusion of MI areas, when assessed by objective quantitative imaging techniques. This randomized pilot SPECT, PET, and MRI study was aimed at assessing the effects of bone marrow mononuclear cells (BMNCs) when implanted in areas of severe and chronic MI. Materials and Methods: Fourteen patients, who were referred for coronary artery bypass grafting (CABG) and in whom a screening MIBI-SPECT revealed severely damaged myocardium (G50% uptake under nitrate), were randomized between a cell therapy group (n = 7; CABG and injection of BMNCs within MI areas) and a control group (n = 7; CABG alone). Results: The MI areas exhibited a posttherapeutic enhancement in the restuptake of MIBI in the cell therapy group [difference between 6-month control and baseline: +6.8% (5.4%), P = 0.03] but not in the control group [+1.0% (4.3%)]. However, in a per-patient analysis, this improvement was significant (9 +9%) in only 3 cell therapy patients, whose MI areas before therapy had a higher FDG uptake [59% (9%) vs 38% (8%), P = 0.03] and a lower transmural extent at MRI [40% (6%) vs 73% (18%), P = 0.03] when compared with the other cell therapy patients. Conclusions: Perfusion enhancement, obtained with BMNCs in areas of chronic MI, might require an intermediate level of viability documented with FDG-PET and MRI and that totally necrotic MI seems refractory to this cell therapy technique.
P revious reports have shown that cardiac cell therapy with unselected bone marrow mononuclear cells (BMNCs) 1Y7 or with selected subtypes 8Y11 is associated with some improvement in myocardial perfusion and cardiac function in patients with recent myocardial infarction (MI). Up to now, however, there have been limited investigations into the chronic phase of MI, 2,12Y14 and many questions remain concerning the contribution of the engrafted cells and especially their impact in late myocardial reperfusion, according to the stage of MI and to its severity. Therefore, by using objective quantitative imaging techniques, this pilot study aimed to determine whether cell therapy with BMNCs offers a real improvement, when applied to patients referred for coronary artery bypass grafting (CABG) and despite the presence of chronic MI areas, commonly considered to be severely damaged by a screening nitrate-enhanced MIBI-SPECT. 15Y17 This randomized study involved a direct comparison between patients treated or not by cell therapy, and it was conducted with a multimodal imaging protocol involving MIBI-SPECT, 18 F-FDG PET, and MRI to provide a comprehensive assessment of the 6-month evolutions of cardiac perfusion, metabolism, and contractility.
MATERIALS AND METHODS

Patient Selection
The study protocol was approved by the local ethical committee and by the French Administration (AFSSAPS, protocol no. TC175), and all study patients gave signed informed consent to participate. These patients were prospectively recruited among those referred for CABG in our institution, with ages ranging from 18 to 75 years and with more than a 2-month history of MI. They were referred to a screening nitrate-enhanced MIBI-gated SPECT and included if they fulfilled the following criteria: (1) left ventricular (LV) ejection fraction (EF) ranging from 30% to 50% and (2) the presence, on the 17-segment model, 18 of at least 2 contiguous LV segments with severe contractility abnormalities and less than 50% of MIBI uptake, a criterion of irreversibly damaged myocardium. 15Y17 Main exclusion criteria were as follows: (1) unstable angina or cardiac insufficiency; (2) congenital or valvular cardiac disease, hypertrophic or idiopathic cardiomyopathy, or LV aneurysm requiring surgery; (3) history of severe arrhythmia (except those occurring at the acute phase of MI); (4) history of cancer; (5) hematologic, immunologic, or inflammatory disease; (6) severe renal disease defined as GFR less than 30 mL/min; (7) chronic liver disease classified as Chil-Pugh class B or C; (8) contraindication to MRI; and (9) women with childbearing potential.
Study Organization
After inclusion, the patients were referred for FDG-PET and MRI. Cardiac surgery was performed less than 15 days after completion of these investigations.
Surgical technical modalities were defined before the randomization process. The myocardial segments with low viability, which were targeted for cell therapy, were defined as those exhibiting an uptake of MIBI under nitrate, which was less than 50% with regard to the maximal LV voxel value 15Y17 and extending over at least 50% of the projected segment area, the segment areas being defined on the 17-segment model. 18 Coronary artery territories requiring CABG were those exhibiting more than 70% stenosis and involving one or more viable segments (ie, segments that were not those with low viability, as defined above).
Patients were randomly assigned to a cell therapy group (CABG and cell therapy) or to a control group (CABG alone) according to 4 matching criteria: (1) sex, (2) age older than 64 years, (3) EF less than 40% at MRI, and (4) severe coronary artery lesions [950% left main coronary artery stenosis, 970% 3-vessel disease, or 970% 2-vessel disease involving the proximal left anterior descending (LAD) artery].
The patients were submitted to a conventional postoperative survey and subsequent controls: (1) at 1 month with a nitrate-enhanced MIBI-gated SPECT and (2) at 6 months for a complete imaging checkup with FDG-PET, MRI, and a rest and nitrate-enhanced MIBI-SPECT, preceded the day before by a stress MIBI-SPECT.
Arrhythmic checkup included a continuous ECG recording using a REVEAL device (Medtronic, Minneapolis, Minn) during a 6-month follow-up period.
Surgical Revascularization and Cell Therapy Procedure
The CABG procedures were performed conventionally under hypothermic blood cardioplegia. Around 100 mL of bone marrow was extracted from the iliac crest of each cell therapy patient just before CABG. Bone marrow mononuclear cells were isolated by Ficoll density gradient, washed with heparinized saline solution, and resuspended in syringes, each containing 10 7 or more BMNCs in 200 KL. In a small aliquot of the cell suspension, cell viability and cell count were analyzed using the trypan blue exclusion technique. About 30 to 40 of these syringes were injected in the targeted myocardial segments of each cell therapy patient, just after the CABG procedure.
MIBI-Gated SPECT Acquisitions
As previously described, 15 4 MBq/kg body weight of 99m Tc-MIBI was injected for the baseline rest acquisition and 12 MBq/kg body weight was reinjected 2 to 3 hours later, 4 to 5 minutes after the sublingual administration of nitroglycerin spray. For the 6-month stress acquisition, 12 MBq/kg body weight was injected at peak exercise or after IV injection of dipyridamole (0.56 mg/kg body weight). All gated SPECT scans were recorded 50 to 70 minutes after tracer injection on a double-head camera (DST-XL; SMV-General Electric, Buc, France). 15 Segmental values of MIBI uptake were determined using the 17-segment model 18 and QPS software. 19 Perfusion of the areas of severe MI was assessed while averaging MIBI uptake values from corresponding segments on the resting SPECT images. Left ventricular volume and EF were obtained on the nitrate-gated SPECT reconstructions with QGS software. 19 Cardiac FDG-PET Patients were premedicated with 250 mg of acipimox given twice at 1-hour intervals. 20 An activity of 370 MBq of FDG was injected intravenously, and 60 minutes later, a 10-minute 3-dimensional PET recording was obtained on a Biograph system involving a 2-detector CT for correction attenuation (Siemens, Knoxville, Tenn). PET images were reconstructed (ordered subset expectation maximization with 3 iterations and 8 subsets), corrected for attenuation and scatter, and displayed into 5.0 Â 5.0 Â 5.0-mm 3 voxels. Segmental values of FDG uptake were determined with QPS software, 19 and the FDG uptake of severe MI area was determined while averaging uptake values from corresponding segments.
Cardiac MRI
Cardiac MRI sequences were recorded on a 1.5-T magnet (Signa Excite; GE Medical Systems, Milwaukee, Wis) as previously described. 21, 22 A steady-state free precession pulse sequence was used for assessing LV function in contiguous short-axis planes, completed by midventricular horizontal and vertical long-axis views. Delayed-enhancement images (3-dimensional myocardial delayed enhancement sequence; GE Medical Systems) were obtained 8 to 12 minutes after the injection of 0.1 mmol/kg of Ga-DTPA (Magnevist; Schering AG, Berlin, Germany).
Contour detection software (MASS; Medis, Leiden, the Netherlands) was used to determine LV end-diastolic and end-systolic volumes, EF, as well as the segmental values of myocardial thickening (percentage of thickness enhancement between end-diastole and endsystole) and of transmural extent of MI. 21, 22 Values of thickness, thickening, and transmural extent of MI were obtained for the entire MI areas while averaging values from corresponding segments.
Statistical Analysis
Continuous variables were expressed as mean (SD), and discrete variables were expressed as percentages. Unpaired 2-group comparisons were performed with Mann-Whitney tests for continuous variables and Fisher exact tests for discrete variables. Wilcoxon tests were used for paired comparisons of continuous variables. P G 0.05 was considered to indicate a statistical significance.
RESULTS
Baseline Patient Characteristics, Cardiac Surgery, and Cell Therapy
Fourteen patients with a mean age of 57 (10) years were included. All but 1 were men, and mean delay between MI and inclusion was 7.2 (7.5) months. Mean EF was 40% (7%) at MRI, and the MI areas involved a mean number of 3.7 (1.1) segments. These areas were in the LAD territory in 9 cases (64%), and they exhibited 45% (7%) of MIBI uptake at rest, 45% (12%) of FDG uptake, 13% (17%) of Among the 14 patients, 10 (71%) had severe CAD lesions at angiography (6 with 3-vessel disease and 4 with 2-vessel disease involving proximal LAD). Left internal mammary artery was grafted on the LAD artery in all 14 patients, and additional bypasses were grafted on diagonal branches (4 patients), right coronary arteries (4 patients), and on left circumflex arteries (8 patients). The MI areas were included in CABG territories in all but 2 patients (1 control and 1 cell therapy patient).
On average, 342 (41) million BMNCs were injected within the MI areas of cell therapy patients. The mean percentage of viable BMNCs was 97% (1%), and percentages of hematopoietic stem cells (CD45 + /CD34 + ) and of mesenchymal stem cells (CD73 + /CD14 j / CD45 j ) were 3% (1%) and 0.2% (0.6%), respectively.
As detailed in Table 1 , there was no significant difference between both groups for the main baseline data.
Safety Data
No patient had any perioperative MI or any severe arrhythmia recorded by REVEAL. The 6-month stress-SPECT revealed ischemic areas in the CABG territories in 3 of the 7 cell therapy patients and in none of the control group (43% vs 0%, P = 0.1). Bypass graft occlusions were documented by angiography in these 3 patients (1 arterial and 2 venous grafts). Two patients were treated by coronary angioplasty, 1 patient was treated by antianginal medications only, and none had any cardiac events during the subsequent 2-year follow-up.
Functional Cardiac Changes During Follow-up
As detailed in Table 2 , there was no difference between the 2 groups for the 6-month evolutions of all cardiac variables, except for the rest MIBI uptake in MI areas, for which the difference with the baseline was higher in the therapy group than in the control group [+6.8% (5.4%) vs +1.0% (4.3%), P = 0.04]. This difference was already documented at 1 month, although it was not statistically significant (Fig. 1) .
The 6-month enhancement in the restYuptake of MIBI was significant for the overall cell therapy group (P = 0.03), but in a perpatient analysis, it was clearly significant (absolute difference 99% 15 ) in only 3 patients (Table 3 ). These 3 responders had concomitant improvements in the myocardial thickening of MI areas (from 16% to 22%, from 32% to 38%, and from 11% to 20%, respectively), but the 3 patients were also those exhibiting early bypass dysfunction, as already detailed above.
At baseline, these 3 responders had a very low resting uptake of MIBI in the MI areas [40% (2%)], equivalent to that of the 4 nonresponders [42% (9%)], but they had evidence of an intermediate MI severity with higher FDG uptake [59% (9%) vs 38% (8%), P = 0.03] and lower transmural extent of MI at MRI [40% (6%) vs 73% 18%), P = 0.03] compared with the 4 nonresponders. These results are illustrated in 1 cell therapy patient who had an intermediate level of viability and subsequent improvement in perfusion ( Fig. 2) and in another who did not (Fig. 3) .
By contrast, no patient from the control group had an improvement in the perfusion of MI areas at 6 months (difference in MIBI uptake at rest 99% 15 ), even among the 3 showing an intermediate viability and equivalent FDG uptake [54% (2%)] and of transmural extent of MI [41% (8%)] to the 3 responders to cell therapy.
DISCUSSION
By using an objective quantitative SPECT, PET, and MRI survey, this study aimed to determine whether cell therapy with BMNCs Note that only cell therapy patients 1, 2, and 3 had a significant increase in MIBI uptake between baseline and control (absolute difference 99% 15 ). offers a real improvement, when applied to patients referred for CABG despite the presence of chronic MI areas, considered severely damaged by nitrate-enhanced MIBI-SPECT. 15Y17 As expected, perfusion, metabolism, and contractility of these chronic MI areas were not significantly changed in the control group of patients, who only had CABG. By contrast, a posttherapeutic enhancement in the perfusion of MI areas was evidenced by MIBI-SPECT in the cell therapy group. This enhancement was, however, clearly significant in only 3 of the 7 cell therapy patients.
Such an inconstant improvement is close to what we previously observed with bone marrow mesenchymal stem cells in rats. 12 In this animal study, the perfusion enhancement predominated in the less severely damaged MI areas, especially within border zones. In the present clinical imaging study, the 3 responders were also those showing the lowest MI severity with the highest FDG uptake and the lowest transmural extent of MI at MRI. None of these 3 responders had a fully transmural MI at MRI, their mean transmural extent being around 40%.
This 40% level of transmural extent was previously shown to correspond: (1) to a little more than 50% of FDG uptake, 23 which is in accordance with that documented in the present study (mean FDG uptake in MI areas was 59% in the 3 responders patients) and (2) to a poor functional improvement after myocardial revascularization. 24, 25 This last point is confirmed by the lack of clear improvement in the perfusion of the MI areas in any of our control patients, even in those with intermediate viability. This particular condition of intermediate viability is indeed that of a severely and chronically ischemic myocardium, where the cellular loss and the decrease in microvessel density are known to limit the potential for perfusion enhancement. 26 Therefore, our results suggest that, when associated with CABG, BMNCs are able to boost the perfusion enhancement of the MI areas showing intermediate viability. One possible mechanism would be the increase in the angiogenic response to tissue hypoxia. Hypoxia is known to be a potent stimulus for angiogenesis, 27Y29 and the hypoxiarelated angiogenesis was already shown to be enhanced by therapies with bone marrowYderived cells. 27, 30 In the present study, an improvement in the myocardial thickening of the MI area was documented at 6 months in the 3 responders. However, this improvement was limited, without change in the global LV function, confirming the previous finding that bone marrowYderived cells have a limited effect on contractile function. 1, 2, 5, 7 The sole adverse event, which was possibly associated with cell therapy, was a high rate of early bypass dysfunction. This dysfunction was documented in 3 cell therapy patients and in none from the control group. No association between cell therapy and CABG dysfunction has been previously reported, but a high restenosis rate was documented in 2 studies in which coronary angioplasty was associated with cell therapy using either endothelial progenitor cells 8 or granulocyteYcolony-stimulating factor. 31 In addition, the bypass dysfunctions only occurred here in the 3 responders, suggesting that, when significant, the effects of cell therapy could be diffuse and sometimes deleterious at coronary grafting sites. More data are required to warrant the overall safety of BMNC, but our results support a prudent approach to BMNC therapy when associated with CABG during the same surgical procedure.
It must be acknowledged, however, that the sample sizes provided by this pilot study are small, especially those concerning the rare cases of coronary artery bypass dysfunction. Therefore, our results and conclusions need to be confirmed by further studies on larger populations. (1) at baseline, a low MIBI uptake, but signs of at least intermediate viability with a 30% to 40% transmural extent of MI on delayed retention magnetic resonance images and with a more than 50% FDG uptake on anterior wall; and (2) 6-month improvements in resting perfusion (MIBI-SPECT) and in myocardial thickening (cine-MRI). . Vertical (VLA) and horizontal long-axis (HLA) views recorded before treatment (left) and at the 6-month control (right) in a patient with no effect of cell therapy. The anterior, septal, and apical MI area (red arrows) exhibited: (1) at baseline, a less-than-50% uptake for both MIBI and FDG, as well as transmural MI on delayed retention magnetic resonance images; and (2) at 6 months, no improvement in resting perfusion (MIBI-SPECT) and in myocardial thickening (cine-MRI).
In conclusion, this pilot study shows that perfusion enhancement obtained with BMNCs therapy in chronic MI might require an intermediate level of viability documented with FDG-PET and MRI and that totally necrotic MI seems refractory to this therapy. Therefore, FDG-PET and/or MRI could be useful for identifying the patients who might benefit from BMNC therapy.
